Bafna

Executive Summary

Bafna Pharmaceuticals Ltd is an Indian contract research and manufacturing organization (CMO) specializing in solid oral dosage forms for small-molecule drugs. Accredited by EU-GMP, UK-MHRA, and TGA, the company supplies high-quality formulations to regulated markets in the UK, Europe, Australia, and emerging regions. Founded in 2020 and based in Chennai, Bafna leverages advanced formulation technologies to deliver scalable products for pharmaceutical partners. As a private commercial-stage company, it has no publicly traded equity or disclosed funding rounds, but its regulatory accreditations position it competitively in the global CMO market, particularly for generic and branded generic manufacturers seeking cost-effective production in India. The company's focus on regulated markets differentiates it from many domestic players, though its relatively small scale and limited public information constrain visibility. Overall, Bafna represents a niche but credible player in the pharmaceutical outsourcing space, with potential for growth driven by increasing demand for specialized oral solid dosage manufacturing.

Upcoming Catalysts (preview)

• Q3 2026New EU-GMP renewal or expansion inspection85% success
• Q4 2026Major contract win with a top-20 generic pharma company40% success
• Q1 2027Entry into a new regulated market (e.g., Japan or Canada) via regulatory approval30% success